Asymchem Laboratories, Inc.
600 Airport Boulevard
Suite 1000
Morrisville
North Carolina
27560
United States
Tel: 919-468-3884
Fax: 919-468-3916
Website: http://www.asymchem.com.cn/
Email: info@asymchem.com
About Asymchem Laboratories, Inc.
Asymchem is a USFDA and TGA inspected CMC CDMO with over 20 years' expertise in developing innovative and sustainable processes for development to commercial APIs and HPAPIs.
YEAR FOUNDED:
1995
LEADERSHIP:
CEO: Hao Hong
CSO: James Gage
21 articles about Asymchem Laboratories, Inc.
-
Asymchem Announces Opening of R&D site near Boston, Massachusetts
12/19/2022
Asymchem Laboratories Co., Ltd. announced their opening of a new site in Woburn, Massachusetts – Asymchem Boston, a wholly owned subsidiary of Asymchem Group, as an important step to expand Asymchem's global footprint.
-
AUM Biosciences and Asymchem Complete Phase II API Production Campaign of Novel TRK Inhibitor
10/20/2022
Asymchem and AUM Biosciences jointly announced today the completion of their first GMP production campaign of AUM601.
-
Asymchem Completes Construction on Two New Production Sites
4/6/2022
Asymchem Laboratories Co., Ltd., a leading CDMO serving the global pharmaceutical and biotech industry, announced the company has completed construction of a new building at its Dunhua, China, production site.
-
Asymchem Acquires Snapdragon Chemistry
2/11/2022
Asymchem Laboratories (Tianjin) Co., Ltd. (stock code: 002821.SZ/6821.HK) ("Asymchem"), a leading CDMO serving the global pharmaceutical and biotech industry, today announced its agreement to acquire Snapdragon Chemistry, Inc.
-
AUM Biosciences Identifies Asymchem as the CDMO Partner of Choice for their Novel TRK inhibitor
1/11/2022
Asymchem, a leading global contract development and manufacturing service provider, and AUM Biosciences, a global clinical stage biotech company, focused on discovering, acquiring and developing next generation targeted oncology therapeutics, jointly announced a collaboration agreement.
-
Asymchem Announces Shares Listing on the Hong Kong Exchange (HKE)
12/10/2021
Asymchem is pleased to announce its debut on the Hong Kong Exchange (HKE) through a public offering of H shares.
-
Asymchem Expands Manufacturing Capacity for Oligonucleotides
3/25/2021
Asymchem, is excited to announce a dedicated expansion of our API manufacturing facilities to provide clients with peptide and oligonucleotide products and meet the research and development needs of this expanding area of therapeutics.
-
Asymchem Assures Business Continuity Amid the COVID-19 Outbreak
2/24/2020
Asymchem announced that manufacturing operations had resumed on February 10, 2020, one week after a government required extended New Year holiday due to the novel coronavirus outbreak.
-
Successful USFDA inspection of Asymchem Dunhua 1 API manufacturing facility
5/31/2019
Asymchem announced that its Dunhua 1 site, a small molecule custom manufacturing API facility, successfully completed a U.S. Food and Drug Administration general GMP reinspection conducted between April 8-12, 2019.
-
Successful USFDA inspection of Asymchem Tianjin 2 development and commercial manufacturing facility
9/13/2018
Asymchem today announced that its Tianjin 2 site, a multi-purpose development and commercial API manufacturing facility, successfully passed the U.S. Food and Drug Administration (USFDA) general GMP reinspection conducted between July 23-26, 2018 with no Form 483 issued.
-
Successful USFDA inspection of Asymchem Fuxin 1 carbapenem manufacturing facility
6/1/2018
Asymchem announced that its Fuxin 1 site, a dedicated carbapenem manufacturing facility, successfully passed the U.S. Food and Drug Administration (USFDA) general GMP reinspection conducted between March 12-15, 2018.
-
Asymchem Dunhua Manufacturing Facility Successfully Completes Korean MFDS Inspection
11/30/2017
The 3-day inspection was conducted between September 5-7, 2017 for a customer specific intermediate product which is manufactured, packed and distributed by Asymchem's Dunhua site.
-
Asymchem Dunhua Manufacturing Facility Successfully Completes Second Australian TGA Inspection
10/19/2017
Asymchem today announced that its API facility, Jilin Asymchem Laboratories Co., Ltd. in P.R. China, ("Dunhua"), has successfully passed an inspection by the Australian Therapeutic Goods Administration (TGA) for the second consecutive time.
-
Asymchem Laboratories, Inc., A Tianjin CMO, Raises $125 Million In Shenzhen IPO
11/21/2016
-
Asymchem Laboratories, Inc. Announces Its Initial Public Offering
11/17/2016
-
Asymchem Laboratories, Inc. Opens Large-Scale CMO Facility in Jilin Province
2/17/2012
-
Asymchem Laboratories, Inc. Announces $20MM Investment in New Dunhua Commercial Manufacturing Facility
2/16/2012
-
Dr. Li Qun Joins Asymchem Laboratories, Inc. as Vice President of Medicinal Chemistry
11/2/2011
-
Dr. Chunhao Zhang Joins Asymchem
6/3/2010
-
Asymchem Announces SFDA Certification for Drug Product Manufacturing
6/4/2009